Live Quote · NASDAQXTLBHealthcare· Biotechnology

XTL Biopharmaceuticals Ltd.

$2.70 8.43%(+$0.21)
TickerSpark Score
51/100
Mixed
100
Valuation
20
Profitability
55
Growth
28
Health
50
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XTLB research report →

52-Week Range8% of range
Low
$2.01
Current
$2.70
High
$10.28
Company Overviewwww.xtlbio.com

About the company

XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome.

CEO
Noam Band
IPO
2005
Employees
10
HQ
Ramat Gan, IL

Price Chart

-43.75% · this period
$8.20$5.13$2.06Jul 02Dec 31Jul 02
Valuation
Market Cap
$6.39M
P/E
-0.79
P/S
0.00
P/B
-22.39
EV/EBITDA
-8.24
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-269.02%
ROIC
-11253.33%
Growth & Income
Revenue
$0 · -100.00%
Net Income
$-6,969,000 · -578.58%
EPS
$-68.00 · 100.00%
Op Income
$-1,688,000
FCF YoY
38.70%
Performance & Tape
52W High
$10.28
52W Low
$2.01
50D MA
$2.62
200D MA
$3.35
Beta
0.56
Avg Volume
1.98M

Get TickerSpark's AI analysis on XTLB

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Mar 18, 26Hillel Fain Osnatother1,000,000
Mar 18, 26Segal Nivother0
Nov 18, 08EDELMAN JOSEPHsell24,681,360
Nov 18, 08EDELMAN JOSEPHsell2,696,450
Nov 19, 08EDELMAN JOSEPHsell9,600,000
Nov 18, 08EDELMAN JOSEPHsell29,740
Nov 18, 08EDELMAN JOSEPHsell400,000
Nov 18, 08EDELMAN JOSEPHsell1,943,250
Nov 18, 08EDELMAN JOSEPHsell400,000
Nov 18, 08EDELMAN JOSEPHsell299,570
Coverage · XTLB

Our XTLB coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on XTLB yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate XTLB report →
Internal Compare

Similar companies

Peers in the same neighborhood.